180 Life Sciences EV/EBITDA
¿Qué es el EV/EBITDA de 180 Life Sciences?
El EV/EBITDA de 180 Life Sciences Corp. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con 180 Life Sciences
¿Qué hace 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Empresas con ev/ebitda similar a 180 Life Sciences
- Halo Collective tiene EV/EBITDA de N/A
- Genetron Ltd tiene EV/EBITDA de N/A
- Immunome tiene EV/EBITDA de N/A
- CuriosityStream tiene EV/EBITDA de N/A
- Cornerstone FS Plc tiene EV/EBITDA de N/A
- Yuxing InfoTech Investment tiene EV/EBITDA de N/A
- 180 Life Sciences tiene EV/EBITDA de N/A
- Anglo African Oil & Gas Plc tiene EV/EBITDA de N/A
- North Peak Resources tiene EV/EBITDA de N/A
- Casablanca tiene EV/EBITDA de N/A
- Predictive Oncology tiene EV/EBITDA de N/A
- Theranexus SA tiene EV/EBITDA de N/A
- 49 North Resources tiene EV/EBITDA de N/A